Autolus Therapeutics Bolsa (NASDAQ: AUTL)

Últimas noticias sobre Autolus Therapeutics (NASDAQ:AUTL) Bolsa

Autolus Therapeutics

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics PLC

Austal Ltd

WIIM

IIPR

CORRECTION: Innovative Industrial Properties shares are trading lower.

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) with a Buy and lowers the price target from $7 to $5.

News

Price Target

Reiteration

Analyst Ratings

PYXS

HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Lowers Price Target to $5

Molecular Templates Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares are trading lower by 60% to 13 cents during Friday&#8217;s session after the company announced it received a Nasdaq <a href="https://www.benzinga.com/pressreleases/24/12/g42603890/molecular-templates-announces-notice-of-delisting-and-failure-to-satisfy-continued-listing-rules">delisting notice</a>.
What To Know: Molecular Templates, a clinical-stage biopharmaceutical company developing cancer therapies, announced it has received notice from Nasdaq regarding the delisting of its securities. 
The Nasdaq Listing Qualifications Department cited the company's classification as a &#8220;public shell&#8221; and its failure to comply with key listing requirements. These include not filing its quarterly report for the third-quarter 2024 and failing to maintain the minimum $1.00 bid price for its stock.
Trading of Molecular Templates&#8217; common stock is set to be suspended on December 26. The company says it does not intend to appeal Nasdaq&#8217;s decision, and delisting will be formalized with the U.S. Securities and Exchange Commission following the suspension.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42615908/feds-preferred-inflation-gauge-falls-more-than-expected-markets-breathe-sigh-of-relief">Fed&#8217;s Preferred Inflation Gauge Falls More Than Expected: Markets Breathe Sigh Of Relief</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, MTEM has a 52-week high of $4.12 and a 52-week low of $0.30.

MTEM

Why Molecular Templates (MTEM) Stock Is Down 60%

<a href="https://www.benzinga.com/topic/european-commission" target="_blank" rel="noreferrer noopener">The European Commission</a> granted unconditional approval Thursday for Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to acquire Run:ai Labs Ltd, an Israel-based provider of GPU orchestration software.
The decision under the EU Merger Regulation concluded the acquisition would not raise competition concerns within the European Economic Area.
Nvidia, a U.S.-based leader in GPU technology for data centers, gaming and automotive applications, aims to integrate Run: ai&#8217;s software into its ecosystem. Run:ai specializes in software that helps organizations optimize and manage their artificial intelligence compute workloads across various environments, including on-premises and cloud platforms.
The commission&#8217;s investigation focused on whether the merger could harm competition in two critical markets: discrete GPUs for data centers and GPU orchestration software.
Although Nvidia holds a dominant position in the global market for data center GPUs, the inquiry determined the company lacks the technical ability and motivation to limit compatibility between its GPUs and competing software solutions. Similarly, Run:ai does not command a significant market share in GPU orchestration software, ensuring continued access to alternative providers for customers.
Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) and Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) server products embedded Nvidia AI chips.
Some customers replicated serial numbers of the servers containing Nvidia chips purchased from Super Micro and attached them to other servers.
Also, smugglers altered the serial numbers in the server operating system.
Dell and Super Micro said they complied with the regulatory norms.
U.S. Big Tech giants have drawn intense regulatory scrutiny for allegedly trying to stifle fair competition by exploiting their influence.
In 2024, <a href="https://www.benzinga.com/government/24/11/41685490/nvidias-run-ai-acquisition-draws-european-regulatory-scrutiny-on-competition-concerns" target="_blank" rel="noreferrer noopener">U.S. regulatory bodies</a>, including the Department of Justice&#8217;s antitrust division, reviewed Nvidia&#8217;s potential dominance within the AI chip sector. The Federal Trade Commission was also examining investments by the Big Tech giants.
Nvidia&#8217;s plans to purchase British chip designer Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) succumbed to global regulatory opposition. Other significant acquisitions that failed to win regulatory approval included Broadcom Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) plans to acquire Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>).
Meanwhile, the U.S. Department of Commerce urged Nvidia&nbsp;to investigate how the company&#8217;s products reached China by flouting the semiconductor embargo, Reuters reported, citing The Information.
The Biden Administration slapped semiconductor sanctions on China by restricting its access to advanced artificial intelligence technology chips and equipment meant to produce the chips.
Nvidia urged leading distributors like Super Micro Computer and Dell to conduct spot checks of Southeast Asian customers.
Nvidia stock surged over 171% year-to-date. Investors can gain exposure to the stock through VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) and Fidelity MSCI Information Technology Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTEC#NYSE">FTEC</a>).
NVDA Price Action:&nbsp;Nvidia stock is up 1.74% at $132.95 at publication Friday.
Photo: Shutterstock

Government

Regulations

Global

Tech

Media

AVGO

DELL

FTEC

NVDA

QCOM

SMCI

Nvidia Secures EU Approval For Run:ai Deal, US Probes China Export Breach

Jefferies analyst Laurence Alexander maintains FuelCell Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) with a Hold and lowers the price target from $15 to $8.4.

FCEL

Jefferies Maintains Hold on FuelCell Energy, Lowers Price Target to $8.4

Trading Ideas

YAAS

Youxin Technology Shares Resume Trade

Lululemon Athletica Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) shares initially dipped 2% to $366.00 Friday morning following Nike&#8217;s second-quarter earnings report and <a href="https://www.benzinga.com/24/12/42610441/nikes-new-ceo-says-we-lost-our-obsession-with-sport-as-he-rebukes-old-strategies-on-performance-marketing-isolation-of-wholesalers-aims-to-create-demand">strategic pivot</a> under its new CEO, Elliott Hill. Nike shares fell 5.5% to $72.86 Friday morning following the report.
What To Know: Nike's report highlighted better-than-expected earnings, with revenue reaching $12.35 billion, surpassing Wall Street estimates. 
However, Hill's <a href="https://www.benzinga.com/pressreleases/24/12/b42604084/nike-inc-reports-fiscal-2025-second-quarter-results">comments</a> about Nike regaining its dominance by reinvigorating its athlete-first approach, enhancing wholesale relationships, and leveraging value channels like Nike Value Stores to address inventory challenges signal a potential shakeup in market dynamics.
Lululemon has built its success on premium pricing, yoga-inspired apparel, and direct-to-consumer strategies. With Nike now pledging to &#8220;reinvest in brand stories&#8221; and reconnect with wholesale channels, analysts fear the competitive landscape could shift, drawing consumers away from Lululemon's niche. 
Nike's commitment to balancing digital and physical retail, as highlighted in the second-quarter <a href="https://www.benzinga.com/pressreleases/24/12/b42604084/nike-inc-reports-fiscal-2025-second-quarter-results">report</a>, could also pose risks to Lululemon&#8217;s omnichannel strategy.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42615908/feds-preferred-inflation-gauge-falls-more-than-expected-markets-breathe-sigh-of-relief">Fed&#8217;s Preferred Inflation Gauge Falls More Than Expected: Markets Breathe Sigh Of Relief</a>
<h2 class="wp-block-heading">How To Buy LULU Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>)'s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, LULU has a 52-week high of $516.37 and a 52-week low of $226.19.

LULU

What's Going On With Lululemon (LULU) Stock?

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) from Hold to Hold.

NBIX

Needham Reiterates Hold on Neurocrine Biosciencesto Hold

Abpro Shares Resume Trading Following Circuit Breaker Halt

Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) from Hold to Hold.

VRCA

Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

U.S. stocks were higher, with the Dow Jones index gaining over 300 points on Friday.
Shares of Mission Produce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVO#NASDAQ">AVO</a>) rose sharply during today's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/12/42605747/mission-produce-shares-grow-after-strong-q4-results-details">better-than-expected fourth-quarter sales results.</a>
Mission Produce reported quarterly earnings of 28 cents per share and quarterly revenue of $354.4 million, which beat the analyst consensus estimate of $220.4 million.
Mission Produce shares jumped 22.3% to $15.07 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Humacyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares jumped 55.2% to $5.37 after the company announced FDA approval for SYMVESS for treating extremity vascular injuries. HC Wainwright &amp; Co. raised its price target on the stock from $12 to $15.</li>
<li>Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) gained 32% to $6.94 after the company and Moderna recently announced a multi-year extension to continue utilizing the Personalis ImmunoID NeXT platform and technology for V940/mRNA-4157. The company also announced an investment from Merck.</li>
<li>Enovix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) gained 22% to $9.80 as the company shipped first EX-2M samples to mobile phone customers.</li>
<li>Clearwater Paper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLW#NYSE">CLW</a>) surged 21.2% to $29.96.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) gained 20.2% to $8.99.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) gained 20% to $18.17. In an exchange filing dated December 20, Quantum Computing has registered up to 8.96 million shares for resale by selling stockholders.</li>
<li>BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) surged 20% to $3.58 as the company posted upbeat quarterly earnings.</li>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) gained 15.5% to $ 43.63. Craig-Hallum analyst Richard Shannon maintained IonQ with a Buy and raised the price target from $22 to $45.</li>
<li>Sirius XM Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) rose 10% to $22.59. Warren Buffett acquired 4.96 million Sirius XM shares at an average price of $21.60.</li>
<li>Plug Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) gained 9.7% to $2.5248.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) rose 9% to $2.8650.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) gained 6.6% to $13.93.</li>
<li>Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) gained 4.7% to $47.47 after Berkshire Hathaway increased its stake in the company.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) rose 2.1% to $133.38. The European Commission on Thursday announced it approved the proposed acquisition of Run:ai Labs by NVIDIA.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42616304/top-3-risk-off-stocks-that-may-collapse-this-month">Top 3 Risk Off Stocks That May Collapse This Month</a></li>
</ul>

Intraday Update

Markets

Movers

ENVX

HUMA

IONQ

LCID

PLUG

PSNL

QUBT

RGTI

RIVN

SIRI

Mission Produce, Nvidia, Humacyte, BlackBerry And Other Big Stocks Moving Higher On Friday

On Monday, the Nebraska Attorney General filed a lawsuit against UnitedHealth Group&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Change Healthcare Inc., and Optum Inc., alleging severe violations of Nebraska&#8217;s Consumer Protection Act and other laws following a data breach that exposed sensitive information of 575,000 Nebraskans.
The lawsuit accuses the defendants of failing to prevent the breach and mishandling its aftermath, which disrupted healthcare services statewide.
The breach, first disclosed in February this year via UnitedHealth&#8217;s filing with the Securities and Exchange Commission, was initially downplayed as an &#8220;isolated&#8221; <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/02/37284799/whats-going-on-with-unitedhealth-stock-friday" rel="noreferrer noopener">cybersecurity threat</a>.
However, the shutdown of Change Healthcare&#8217;s systems triggered a healthcare crisis, halting medical claims <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/04/38388554/patient-data-compromised-unitedhealth-group-admits-ransom-payment-in-cyberattack" rel="noreferrer noopener">processing for millions of transactions</a>.
Nebraska&#8217;s healthcare providers struggled to maintain operations as critical services like prior authorizations for prescriptions and patient care were delayed.
The <a target="_blank" href="https://ago.nebraska.gov/sites/default/files/doc/Court%20Filing_10.pdf" rel="noreferrer noopener">lawsuit</a> alleges that outdated systems, inadequate segmentation, and the lack of redundancies at Change Healthcare exacerbated the crisis.
The shutdown, which lasted from late February to mid-March 2024, caused severe operational disruptions, leaving healthcare providers to deliver care without compensation and creating opportunities for scammers to <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/03/37989390/unitedhealths-cyberattack-company-provides-aid-of-over-3b-to-affected-providers" rel="noreferrer noopener">target affected patients</a>.
A survey by the American Hospital Association reported that 74% of hospitals experienced direct impacts on patient care, with larger health systems reportedly losing over $100 million daily during the outage.
Despite the significant fallout, the defendants delayed notifying affected individuals. Direct communication to victims began only in late July 2024, five months after the breach was discovered, and even then, not all affected individuals were notified.
The Attorney General&#8217;s office asserts that this delay violates Nebraska law and left residents vulnerable to identity theft and financial harm.
The lawsuit seeks to hold UnitedHealth, Change Healthcare, and Optum accountable for the breach and its cascading effects on Nebraska&#8217;s citizens and healthcare infrastructure.
Price Action: UNH stock is up 1.12% at $494.72 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42615254/winnebago-industries-stock-falls-after-q1-earnings-miss-amid-challenging-marine-operating-environment" target="_blank" rel="noreferrer noopener">Winnebago Industries Stock Falls After Q1 Earnings Miss Amid Challenging Marine Operating Environment</a></li>
</ul>
Image via Shutterstock

Large Cap

Health Care

Legal

General

Nebraska Attorney General Sues UnitedHealth Over Massive Data Breach That Disrupted Healthcare

Youxin Technology Shares Halted On Circuit Breaker To The Upside

DA Davidson analyst Linda Bolton Weiser maintains Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) with a Neutral and lowers the price target from $11 to $7.

DA Davidson Maintains Neutral on Nu Skin Enterprises, Lowers Price Target to $7

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Buy and maintains $102 price target.

VKTX

HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target

IPOs

Youxin Technology Shares Open For Trade At $4.08/Share; IPO Priced At $4.50/Share On 2.3M Shares

Joby Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares are rising after the company announced it has entered the final phase of<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> certification for its electric air taxi.</a>
The company recently conducted its first FAA testing under Type Inspection Authorization, marking a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42611978/joby-successfully-conducts-first-faa-testing-under-tia-begins-final-phase-of-certification-program" rel="noreferrer noopener">major milestone in the aircraft&#8217;s certification process.</a>
The testing involved FAA pilots evaluating human factors elements of flight safety using a Joby simulator with an FAA-conforming flight deck.
TIA is the final phase before the aircraft can begin commercial passenger operations and involves validating the aircraft&#8217;s performance and safety according to previously-approved test plans.
&#8220;This milestone demonstrates Joby&#8217;s continued industry leadership and is a reflection of the maturity of our test program and the rigorous company testing we&#8217;ve already completed,&#8221; said JoeBen Bevirt, CEO and Founder at Joby Aviation.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42618676/this-s-here-are-top-5-initiations-for-friday" rel="noreferrer noopener">This S&amp;P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday</a>
The company is targeting the start of TIA flight testing in 2025 with its first FAA-conforming aircraft, currently being built at Joby&#8217;s facility in Marina, California.
Joby has already completed extensive testing, including &#8216;for credit&#8217; testing of components and systems, and static load testing on its tail structure, marking another significant achievement.
Joby&#8217;s electric air taxi is designed to carry a pilot and up to four passengers at speeds of up to 200 mph, offering high-speed mobility with minimal noise and zero emissions.
With over 40% of the fourth stage of FAA certification already completed, Joby continues to lead the eVTOL space, remaining on track to transform urban air mobility.
Price Action: JOBY shares are trading higher by 4.01% to $7.520 at last check Friday.
Read This Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock" target="_blank" rel="noreferrer noopener">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>
Photo: Joby Aviation.

Equities

JOBY

Joby Aviation Enters Final FAA Certification Phase, Shares Take Off

Compass Point analyst Merrill Ross downgrades Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) from Buy to Neutral and lowers the price target from $125 to $78.

Downgrades

Compass Point Downgrades Innovative Ind Props to Neutral, Lowers Price Target to $78

Financial giants have made a conspicuous bearish move on SoundHound AI. Our analysis of options history for SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) revealed 17 unusual trades.
Delving into the details, we found 41% of traders were bullish, while 52% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $168,730, and 13 were calls, valued at $1,216,924.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $25.0 for SoundHound AI over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for SoundHound AI's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of SoundHound AI's whale trades within a strike price range from $10.0 to $25.0 in the last 30 days. 
<h3>SoundHound AI Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734709533_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOUN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.1</td>
<td>$5.95</td>
<td>$5.95</td>
<td>$15.00</td>
<td>$297.5K</td>
<td>7.5K</td>
<td>6.6K</td>
</tr>
<tr>
<td>SOUN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.05</td>
<td>$5.95</td>
<td>$5.95</td>
<td>$15.00</td>
<td>$296.9K</td>
<td>7.5K</td>
<td>6.8K</td>
</tr>
<tr>
<td>SOUN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$7.4</td>
<td>$7.25</td>
<td>$7.3</td>
<td>$10.00</td>
<td>$146.0K</td>
<td>11.7K</td>
<td>52</td>
</tr>
<tr>
<td>SOUN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$7.5</td>
<td>$7.25</td>
<td>$7.5</td>
<td>$15.00</td>
<td>$75.0K</td>
<td>1.2K</td>
<td>103</td>
</tr>
<tr>
<td>SOUN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$3.2</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$25.00</td>
<td>$62.0K</td>
<td>2.4K</td>
<td>530</td>
</tr>
</tbody>
</table>

<h3>About SoundHound AI</h3>
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers.
In light of the recent options history for SoundHound AI, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>SoundHound AI's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 34,100,981, the SOUN's price is up by 3.21%, now at $19.46. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 69 days.</li>
</ul>
<h3>What The Experts Say On SoundHound AI</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $22.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wedbush has decided to maintain their Outperform rating on SoundHound AI, which currently sits at a price target of $22. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for SoundHound AI, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

SOUN

A Closer Look at SoundHound AI's Options Market Dynamics

Deep-pocketed investors have adopted a bearish approach towards Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in WMT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Walmart. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 20% leaning bullish and 73% bearish. Among these notable options, 9 are puts, totaling $769,950, and 6 are calls, amounting to $201,928.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $73.33 and $95.0 for Walmart, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Walmart's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Walmart's significant trades, within a strike price range of $73.33 to $95.0, over the past month.
<h3>Walmart Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734709528_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/24/25</td>
<td>$0.95</td>
<td>$0.86</td>
<td>$0.92</td>
<td>$88.00</td>
<td>$333.5K</td>
<td>40</td>
<td>3.6K</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.02</td>
<td>$2.01</td>
<td>$2.02</td>
<td>$92.50</td>
<td>$90.4K</td>
<td>4.4K</td>
<td>1.4K</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.96</td>
<td>$1.95</td>
<td>$1.96</td>
<td>$92.50</td>
<td>$67.8K</td>
<td>4.4K</td>
<td>895</td>
</tr>
<tr>
<td>WMT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.0</td>
<td>$0.92</td>
<td>$0.92</td>
<td>$73.33</td>
<td>$64.7K</td>
<td>205.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>WMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$5.95</td>
<td>$5.9</td>
<td>$5.95</td>
<td>$90.00</td>
<td>$54.7K</td>
<td>3.4K</td>
<td>127</td>
</tr>
</tbody>
</table>

<h3>About Walmart</h3>
Walmart serves as the preeminent retailer in the United States, with its strategy predicated on superior operating efficiency and offering the lowest priced goods to consumers to drive robust store traffic and product turnover. Walmart augmented its low-price business strategy by offering a convenient one-stop shopping destination with the opening of its first supercenter in 1988.Today, Walmart operates over 4,600 stores in the United States (5,200 including Sam's Club) and over 10,000 locations globally. Walmart generated over $440 billion in domestic namesake sales in fiscal 2024, with Sam's Club contributing another $86 billion to the company's top line. Internationally, Walmart generated $115 billion in sales. The retailer serves around 240 million customers globally each week.
In light of the recent options history for Walmart, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Walmart Standing Right Now?</h3>
<ul>
<li>With a trading volume of 7,608,341, the price of WMT is down by -0.75%, reaching $92.7.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 62 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Walmart</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $102.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on Walmart with a target price of $90. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Buy rating on Walmart with a target price of $111. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Hold rating on Walmart with a target price of $94. 
&#x2A; Consistent in their evaluation, an analyst from Tigress Financial keeps a Buy rating on Walmart with a target price of $115. 
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Walmart, which currently sits at a price target of $100. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Walmart options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Behind the Scenes of Walmart's Latest Options Trends

Autolus Therapeutics plc 2024 Q3 - Results - Earnings Call Presentation

Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript

Redburn Atlantic upgraded Autolus Therapeutics (AUTL) to Buy from Neutral with an unchanged price target of $13. One week earlier than expected, Au...

Autolus Therapeutics upgraded to Buy from Neutral at Redburn Atlantic

Autolus Therapeutics (AUTL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rajan Sharma fr...

Autolus Therapeutics: FDA Approval of Aucatzyl De-Risks Platform, Significant Upside Anticipated

Goldman Sachs upgraded Autolus Therapeutics (AUTL) to Buy from Neutral with a price target of $7.60, up from $7. The recent approval of lead asset ...

Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Needham analyst Gil Blum maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) yesterday and set a price target of $10.00. Gil B...

Positive Outlook for Autolus Therapeutics Driven by Regulatory Approval and Competitive Positioning in CAR-T Therapy

Analyst Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report) and keeping the price target at $10.00. Gil ...

Autolus Therapeutics: Undervalued Potential in ALL Treatment with Obe-cel

Warning: AUTL is at high risk of performing badly

Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations at the American Society of Hematology Annual Meeting, bei...

Autolus Therapeutics presents clinical data updates at ASH meeting

AUTL

GILD

NVSEF

Earnings

Press Releases

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

Management

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Comments

Autolus Therapeutics

Noticias

Últimas noticias sobre Autolus Therapeutics (NASDAQ:AUTL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL